Carla M Canuso

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension
    Chris M Kozma
    University of South Carolina, Columbia, SC, USA
    Ann Gen Psychiatry 9:24. 2010
  2. ncbi Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms
    C M Canuso
    Ortho McNeil Janssen Scientific Affairs, LLC, 1125 Trenton Harbourton Road, Titusville, NJ 08560 0200, USA
    Schizophr Res 113:56-64. 2009
  3. ncbi Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania
    Carla M Canuso
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ 08560, USA
    Expert Opin Pharmacother 11:2557-67. 2010
  4. ncbi Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers
    Carla M Canuso
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ, USA
    J Clin Psychopharmacol 30:487-95. 2010
  5. ncbi A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder
    Carla M Canuso
    Johnson and Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton Harbourton Rd E12604, Titusville, NJ 08560, USA
    J Clin Psychiatry 71:587-98. 2010
  6. ncbi Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, LLC, 1125 Trenton Harbourton Road A32404, Titusville, NJ 08560, USA
    Int Clin Psychopharmacol 25:155-64. 2010
  7. ncbi Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ 08560 0200, USA
    J Affect Disord 120:193-9. 2010
  8. ncbi Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville New Jersey, USA
    Early Interv Psychiatry 4:64-78. 2010
  9. ncbi Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
    Ibrahim Turkoz
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, New Jersey, USA
    BMC Psychiatry 11:21. 2011
  10. ncbi Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, Titusville, NJ, USA
    Am J Psychiatry 166:691-701. 2009

Detail Information

Publications15

  1. ncbi Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension
    Chris M Kozma
    University of South Carolina, Columbia, SC, USA
    Ann Gen Psychiatry 9:24. 2010
    ..The purpose of this analysis was to evaluate relationships between hospital admission or discharge and scores for symptom or functioning in patients with schizophrenia...
  2. ncbi Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms
    C M Canuso
    Ortho McNeil Janssen Scientific Affairs, LLC, 1125 Trenton Harbourton Road, Titusville, NJ 08560 0200, USA
    Schizophr Res 113:56-64. 2009
    ..Most patients with schizophrenia exhibit negative symptoms, even during acute episodes. These difficult-to-treat symptoms are often associated with poor functioning and outcomes...
  3. ncbi Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania
    Carla M Canuso
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ 08560, USA
    Expert Opin Pharmacother 11:2557-67. 2010
    ..Additional data on its efficacy and safety, including that for additional indications, is emerging...
  4. ncbi Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers
    Carla M Canuso
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, NJ, USA
    J Clin Psychopharmacol 30:487-95. 2010
    ..Paliperidone ER improved psychotic and affective symptoms both as monotherapy and as an adjunct to MS/AD. No new safety findings were observed in this population...
  5. ncbi A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder
    Carla M Canuso
    Johnson and Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton Harbourton Rd E12604, Titusville, NJ 08560, USA
    J Clin Psychiatry 71:587-98. 2010
    ..This study was designed to assess efficacy and safety of paliperidone extended-release (ER) in patients with schizoaffective disorder...
  6. ncbi Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, LLC, 1125 Trenton Harbourton Road A32404, Titusville, NJ 08560, USA
    Int Clin Psychopharmacol 25:155-64. 2010
    ..1%), constipation (7.6%), headache (7.6%) and somnolence (6.6%). Participants with schizophrenia who were suboptimally responsive to risperidone reported improved medication satisfaction after initiation of paliperidone ER...
  7. ncbi Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ 08560 0200, USA
    J Affect Disord 120:193-9. 2010
    ..This post-hoc analysis evaluated the effects of paliperidone extended-release (ER) in patients with schizophrenia and prominent affective symptoms...
  8. ncbi Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, LLC, Titusville New Jersey, USA
    Early Interv Psychiatry 4:64-78. 2010
    ..Effective early and persistent antipsychotic treatment in recently diagnosed schizophrenia may positively impact long-term outcomes. Paliperidone extended-release (ER) was assessed in this population...
  9. ncbi Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
    Ibrahim Turkoz
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Titusville, New Jersey, USA
    BMC Psychiatry 11:21. 2011
    ..To compare the efficacy and tolerability of paliperidone extended-release (ER) with risperidone immediate-release using propensity score methodology...
  10. ncbi Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, Titusville, NJ, USA
    Am J Psychiatry 166:691-701. 2009
    ..The authors compared paliperidone extended-release and quetiapine in patients with recently exacerbated schizophrenia requiring hospitalization...
  11. ncbi Psychotic symptoms in patients with bipolar mania
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs, L L C, Titusville, New Jersey 08560, United States
    J Affect Disord 111:164-9. 2008
    ..Psychosis has been identified in as many as 68% of patients with bipolar mania. This analysis identified psychotic symptoms in these patients...
  12. ncbi Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone
    Carla M Canuso
    Ortho McNeil Janssen Scientific Affairs LLC, Titusville, NJ, USA
    Int Clin Psychopharmacol 23:209-15. 2008
    ..4% with placebo. In patients who had received risperidone previously but remained sufficiently symptomatic for enrollment, paliperidone ER was significantly more effective than placebo in reducing symptoms and producing functional gains...
  13. ncbi Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
    Psychopharmacol Bull 40:41-57. 2007
    ....
  14. ncbi Risperidone for treatment-refractory major depressive disorder: a randomized trial
    Ramy A Mahmoud
    Ortho McNeil Janssen Scientific Affairs, Titusville, New Jersey, USA
    Ann Intern Med 147:593-602. 2007
    ..Major depressive disorder has high prevalence, morbidity, and mortality. Inadequate results with antidepressants have prompts addition of a nonstandard treatment (augmentation therapy)...
  15. ncbi Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
    Ibrahim Turkoz
    Ortho McNeil Janssen Scientific, Affairs, LLC, Titusville, NJ, USA
    Neuropsychiatr Dis Treat 4:949-58. 2008
    ..1% inverse effect. Path analysis indicated that paliperidone ER has a direct effect on negative symptoms. Negative symptom improvement also was indirectly mediated via changes in positive and depressive symptoms...